JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 18, 2007; DOI: 10.1124/jpet.107.127704


0022-3565/08/3241-95-102$20.00
JPET 324:95-102, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.127704v1
324/1/95    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shen, F.
Right arrow Articles by Erickson, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shen, F.
Right arrow Articles by Erickson, L. C.

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Quantitation of Doxorubicin Uptake, Efflux, and Modulation of Multidrug Resistance (MDR) in MDR Human Cancer Cells

Fei Shen, Shaoyou Chu1, Aimee K. Bence, Barbara Bailey, Xinjian Xue, Priscilla A. Erickson, Marshall H. Montrose2, William T. Beck, and Leonard C. Erickson

Departments of Pharmacology and Toxicology (F.S., A.K.B., B.B., X.X., P.A.E., L.C.E.) Indiana University Cancer Center, and Cellular and Integrative Physiology (S.C., M.H.M.), Indiana University School of Medicine, Indianapolis, Indiana; and Department of Biopharmaceutical Sciences, University of Illinois at Chicago, Chicago, Illinois (W.T.B.)

P-glycoprotein (Pgp), a membrane transporter encoded by the MDR1 gene in human cells, mediates drug efflux from cells, and it plays a major role in causing multidrug resistance (MDR). Confocal microscopy was used to study in vitro and in vivo drug accumulation, net uptake and efflux, and MDR modulation by P-glycoprotein inhibitors in MDR1-transduced human MDA-MB-435mdr (MDR) cancer cells. The MDR cells were approximately 9-fold more resistant to the anticancer drug doxorubicin than their parental wild-type MDA-MB-435wt (WT) cells. Doxorubicin accumulation in the MDR cells was only 19% of that in the WT cells. The net uptake of doxorubicin in the nuclei of the MDR cells was 2-fold lower than that in the nuclei of the WT cells. Pgp inhibitors verapamil, cyclosporine A, or PSC833 increased doxorubicin accumulation in the MDR cells up to 79%, and it reversed drug resistance in these cells. In living animals, doxorubicin accumulation in MDA-MB-435mdr xenograft tumors was 68% of that in the wild-type tumors. Administration of verapamil, cyclosporine A, or PSC833 before doxorubicin treatment of the animals increased doxorubicin accumulation in the MDR tumors up to 94%. These studies have added direct in vitro and in vivo information on the capacity of the transporter protein Pgp to efflux doxorubicin and on the reversal of MDR by Pgp inhibitors in resistant cancer cells.


Received June 25, 2007; accepted October 17, 2007.

Address correspondence to: Dr. Leonard C. Erickson, Indiana Cancer Center, Cancer Research Institute, R4-Room 168, 1044 West Walnut St., Indianapolis, IN 46202. E-mail: lcericks{at}iupui.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.